Paradigm Capital
 
Paradigm Home
News
About Paradigm
Paradigm Research
Investment Banking
Sales and Trading
 

 

Knight Therapeutics
Knight Therapeutics
$230,000,000
Co-Manager

June 2016
Prometic Life Sciences
Prometic Life Sciences
$60,100,000
Co-Manager

May 2016
Opsens
Opsens
$5,000,000
Lead

December 2015
Prometic Life Sciences
Prometic Life Sciences
$57,600,000
Co-Manager

May 2015
Prometic Life Sciences
Prometic Life Sciences
$28,800,000
Co-Manager

December 2014
Mettrum
Mettrum
$34,500,000
Co-Manager

July 2014
DIAMEDICA Inc
DIAMEDICA Inc
$2,000,000
Lead
 

July 2014
Merus Labs International Inc
Merus Labs International Inc
$31,300,000
Co-Manager

June 2014
Merus Labs International Inc
Merus Labs International Inc
$23,000,000
Co-Manager  

March 2014
Opsens Inc
Opsens Inc
$8,500,000
Co-Manager  

February 2014
ProMetic Life Sciences
ProMetic Life Sciences
$24,000,000
Lead  

October 2013
Trimel Pharmaceuticals
Trimel Pharmaceuticals
$46,000,000
Lead  

May 2013
Oncolytics Biotech Inc
Oncolytics Biotech Inc
$32,000,000
Lead  

February 2013
Oncolytics BIotech Inc
Oncolytics BIotech Inc
$21,300,000
Lead  

February 2012
Medicago Inc
Medicago Inc
$25,000,000
Co-Lead  

September 2011
Medicago Inc.
Medicago Inc.
$17,400,000
Co-Manager  

April 2011
Paladin Labs Inc.
Paladin Labs Inc.
$40,250,000
Co-Manager
 

February 2011
QHR Technologies Inc.
QHR Technologies Inc.
$8,000,000
Lead  

December 2010
Imris Inc
Imris Inc
$52,500,000
Co-Manager  

November 2010
Oncolytics Biotech Inc.
Oncolytics Biotech Inc.
$28,800,000
Lead
 

November 2010
ImmunoVaccine Inc.
ImmunoVaccine Inc.
$7,470,000
Co-Manager  

September 2010
Medicago Inc.
Medicago Inc.
$7,500,000
Co-Manager  

August 2010
Medicago Inc.
Medicago Inc.
$11,592,000
Lead  

November 2009
<br>Noveko International Inc.

Noveko International Inc.
$15,743,200
Co-Manager  

October 2009
Burcon NutraScience Corporation
Burcon NutraScience Corporation
$17,252,013
Lead  

June 2009

UNPRECEDENTED BREAKTHROUGHS FOR HEALTH AND WEALTH.

New drugs, new treatments, an ageing population.  Our Biotechnology & Health Care team looks to a future with many more cures for patients, as well as opportunities for investors.

To discuss Biotechnology & Health Care transactions please contact:

Ian Joseph
416.363.9561